Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Public ClinicalTrials.gov record NCT00028496. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Study of a Recombinant Fowl Pox Vaccine rF-CEA (6D)/TRICOM Alone or With GM-CSF in Patients With Advanced CEA Expressing Adenocarinomas
Study identification
- NCT ID
- NCT00028496
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 48 participants
Conditions and interventions
Conditions
- Adenocarcinoma of the Colon
- Adenocarcinoma of the Gallbladder
- Adenocarcinoma of the Pancreas
- Adenocarcinoma of the Rectum
- Adult Primary Hepatocellular Carcinoma
- Advanced Adult Primary Liver Cancer
- Cholangiocarcinoma of the Gallbladder
- Diffuse Adenocarcinoma of the Stomach
- Intestinal Adenocarcinoma of the Stomach
- Male Breast Cancer
- Mixed Adenocarcinoma of the Stomach
- Ovarian Endometrioid Adenocarcinoma
- Paget Disease of the Breast With Intraductal Carcinoma
- Paget Disease of the Breast With Invasive Ductal Carcinoma
- Recurrent Adult Primary Liver Cancer
- Recurrent Breast Cancer
- Recurrent Colon Cancer
- Recurrent Gallbladder Cancer
- Recurrent Gastric Cancer
- Recurrent Malignant Testicular Germ Cell Tumor
- Recurrent Pancreatic Cancer
- Recurrent Rectal Cancer
- Recurrent Salivary Gland Cancer
- Salivary Gland Adenocarcinoma
- Stage II Malignant Testicular Germ Cell Tumor
- Stage II Pancreatic Cancer
- Stage III Colon Cancer
- Stage III Gastric Cancer
- Stage III Malignant Testicular Germ Cell Tumor
- Stage III Pancreatic Cancer
- Stage III Rectal Cancer
- Stage III Salivary Gland Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IV Breast Cancer
- Stage IV Colon Cancer
- Stage IV Gastric Cancer
- Stage IV Pancreatic Cancer
- Stage IV Rectal Cancer
- Stage IV Salivary Gland Cancer
- Thyroid Gland Medullary Carcinoma
- Unresectable Gallbladder Cancer
Interventions
- recombinant fowlpox GM-CSF vaccine adjuvant Biological
- recombinant fowlpox-CEA(6D)/TRICOM vaccine Biological
- sargramostim Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2001
- Primary completion
- Oct 31, 2005
- Completion
- Not listed
- Last update posted
- Jan 24, 2013
Started 2001
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111-2497 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00028496, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 24, 2013 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00028496 live on ClinicalTrials.gov.